Literature DB >> 8074717

Amyloid precursor protein secretion via muscarinic receptors: reduced desensitization using the M1-selective agonist AF102B.

R Haring1, D Gurwitz, J Barg, R Pinkas-Kramarski, E Heldman, Z Pittel, A Wengier, H Meshulam, D Marciano, Y Karton.   

Abstract

Secretion of amyloid precursor protein (APP) by cultured cells is coupled to several receptors, including m1 muscarinic (m1AChR), and is associated with decreased production of beta A4 amyloid. Secreted and cell-associated APP levels were measured in m1AChR-transfected PC12 cells stimulated with the non-selective agonist carbachol or the M1-selective agonist, AF102B. Secreted APP levels following stimulation with AF102B (5-60 min) were about half compared with carbachol. Yet, following 24 h stimulation with carbachol or AF102B, cell-associated APP levels were similarly decreased. This may be associated with a smaller reduction in APP secretion following 24 h stimulation with AF102B as compared with carbachol. AF102B may therefore have an advantage over non-selective muscarinic ligands for sustained decrease of cell-associated APP.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8074717     DOI: 10.1006/bbrc.1994.2232

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.

Authors:  Gregory J Digby; Jana K Shirey; P Jeffrey Conn
Journal:  Mol Biosyst       Date:  2010-06-25

2.  Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo.

Authors:  Albert A Davis; Jason J Fritz; Jürgen Wess; James J Lah; Allan I Levey
Journal:  J Neurosci       Date:  2010-03-24       Impact factor: 6.167

Review 3.  M1 muscarinic acetylcholine receptor in Alzheimer's disease.

Authors:  Shangtong Jiang; Yanfang Li; Cuilin Zhang; Yingjun Zhao; Guojun Bu; Huaxi Xu; Yun-Wu Zhang
Journal:  Neurosci Bull       Date:  2014-03-03       Impact factor: 5.203

Review 4.  Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme.

Authors:  Evelin L Schaeffer; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

5.  AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.

Authors:  Abraham Fisher; Rachel Brandeis; Rachel Haring Nira Bar-Ner; Michal Kliger-Spatz; Niva Natan; Hagar Sonego; Itzhak Marcovitch; Zipora Pittel
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

Review 6.  Dangerous Liaisons: Tau Interaction with Muscarinic Receptors.

Authors:  Adrianna Wysocka; Ewelina Palasz; Marta Steczkowska; Grazyna Niewiadomska
Journal:  Curr Alzheimer Res       Date:  2020       Impact factor: 3.498

Review 7.  M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.

Authors:  Abraham Fisher; Zipora Pittel; Rachel Haring; Nira Bar-Ner; Michal Kliger-Spatz; Niva Natan; Inbal Egozi; Hagar Sonego; Itzhak Marcovitch; Rachel Brandeis
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866

8.  The role of Wnt signaling in neuronal dysfunction in Alzheimer's Disease.

Authors:  Nibaldo C Inestrosa; Enrique M Toledo
Journal:  Mol Neurodegener       Date:  2008-07-24       Impact factor: 14.195

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.